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Abstract: The aim of this study was to examine racial differences in long-term mortality 
after coronary artery bypass grafting (CABG), stratified by preoperative use of inotropic 
agents. Black and white patients who required preoperative inotropic support prior to 
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undergoing CABG procedures between 1992 and 2011 were compared. Mortality 
probabilities were computed using the Kaplan-Meier product-limit method. Hazard ratios 
(HR) and 95% confidence intervals (CI) were computed using a Cox regression model.  
A total of 15,765 patients underwent CABG, of whom 211 received preoperative  
inotropic agents within 48 hours of surgery. Long-term mortality differed by race  
(black versus white) among preoperative inotropic category (inotropes: adjusted HR = 1.6,  
95% CI = 1.009–2.4; no inotropes: adjusted HR = 1.15, 95% CI = 1.08–1.2;  
Pinteraction < 0.0001). Our study identified an independent preoperative risk-factor for long-term 
mortality among blacks receiving CABG. This outcome provides information that may be 
useful for surgeons, primary care providers, and their patients.  
Keywords: inotropes; cardiac surgery; mortality; disparities; heart disease; heart failure 
 
1. Introduction 
Inotropic agents are used for the treatment of hypotension and hypoperfusion syndrome in the setting 
of acute decompensated heart failure or cardiogenic shock after acute myocardial infarction (MI) [1]. 
While inotropes have been shown to improve hemodynamics, potential complications associated with 
their use include myocardial ischemia secondary to increased oxygen demand and stunning of 
myocardium in ischemic heart disease. The perioperative use of inotropic agents has been associated 
with increased morbidity and mortality in patients undergoing open heart surgery [2].  
Differences between ethnic groups in responsiveness to several classes of cardiovascular drugs  
(e.g., warfarin, β-blockers, angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers and 
isosorbide-hydralazine) have been well documented [3]. Although short-term outcomes of inotrope use 
among black patients have been examined in the literature, information is generally lacking on the  
long-term effect of their preoperative use in this population [4]. Because ethnicity often is an important 
factor in guiding drug therapy and follow-up care, we sought to explore the differential long-term 
mortality of preoperative inotrope use by race among patients undergoing coronary artery bypass graft 
(CABG) surgery. We hypothesize that long-term mortality would be increased among black patients 
who had ischemic cardiomyopathy and received preoperative inotropes.  
2. Methods 
2.1. Study Design 
This was a retrospective cohort study of 15,765 patients undergoing first-time CABG at the  
East Carolina Heart Institute from 1992 to 2011. Demographic data, medication use, comorbid 
conditions, CAD severity, and surgical data were collected at the time of surgery. Less than 1% of 
patients were races other than black or white and were excluded to minimize the potential for residual 
confounding. Racial identity was self-reported. The study was approved by the Institutional Review 
Board at the Brody School of Medicine, East Carolina University (UMCIRB 12-002107). This was a 
natural history (non-experimental) analysis of an archival de-identified dataset, in consent with the 
Int. J. Environ. Res. Public Health 2015, 12 7480 
 
 
Declaration of Helsinki. Details of the study database and methodology have been previously described 
and are briefly summarized below [5–15]. 
2.2. Definitions 
In this study, patients were categorized into the inotrope group if within the 48 hour window prior to 
surgery they received an inotropic agent (e.g., β-adrenergic agonist: dobutamine, dopamine, epinephrine, 
norepinephrine; phosphodiesterase-III inhibitor: amrinone, enoximone, milirinone, theophylline).  
The patients could have been in acute cardiogenic shock secondary to ischemic heart disease or acute 
decompensated heart failure. Heart failure was defined as having a preoperative diagnosis according to 
standard Society of Thoracic Surgeons (STS) criteria. This included physician documentation or 
confirmatory medical reports (hospital admission notes, chest radiographs, consultations, physical exam, 
medication administration records, outpatient records, and radiology reports). Stable or asymptomatic 
compensated failure or patients whose symptoms improved after medical therapy were not included in 
this definition. Patients with a low ejection fraction without clinical symptoms (edema, rales, paroxysmal 
nocturnal dyspnea) also were not defined as having heart failure. Adjudication review was used to rule 
out non-definitive heart failure diagnoses. Only definitive cases were included in this study.  
CAD severity was defined by the number of diseased vessels (1, 2, or 3) with at least 50% stenosis and 
confirmation by angiography before surgery. Long-term mortality was defined as any cause of death 
occurring postoperatively.  
2.3. Setting 
The East Carolina Heart Institute is a large (>120 beds) cardiovascular hospital located in rural  
North Carolina, a region with a large black population. The institute is the largest stand-alone, tertiary 
referral hospital focusing on diagnoses and treatment of cardiovascular disease in the state of  
North Carolina. Cardiovascular disease is a leading cause of death in North Carolina with an unequal 
burden occurring in eastern North Carolina [16]. The majority of patients treated at the East Carolina 
Heart Institute live and remain within a 150-mile radius of the medical center. 
2.4. Data Collection and Follow-Up 
Study data were extracted from the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery 
Database and the electronic medical record at the Brody School of Medicine. Data quality and  
cross-field validation are routinely performed by the Center for Epidemiology and Outcomes Research 
at the East Carolina Heart Institute. Electronic medical records were first introduced at the Brody School 
of Medicine in 1997. Patient information prior to 1997 was retrospectively scanned into the electronic 
medical record, with complete conversion beginning in 1992. Data on intra/postoperative inotrope use 
was only collected from 1992–2007 (n = 13,751). Local and regional health care providers were networked 
under a single electronic medical record system in 2005 which allowed for efficient follow-up.  
Multiple logic comparisons are applied to the data to reduce mismatching of information across clinics 
and follow-up visits. Our cardiovascular surgical database is linked to the electronic medical record 
through a unique patient medical record number.  
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The catchment area for the East Carolina Heart Institute is relatively stable. In most cases, deaths are 
documented through the regional medical center electronic medical record system, follow-up 
letters/phone calls (primary care providers, patients), death certificates from county registrars, and/or 
obituary notices. The National Death Index was used to validate death information in our electronic 
medical record and complete missing data. Less than 5% of deaths in our database failed to correctly 
match with the National Death Index.  
2.5. Statistical Analysis 
Categorical variables were reported as frequency and percentage while continuous variables were 
reported as median and interquartile range. Follow-up time was computed from the date of surgery to 
the date of death or censoring. The Kaplan-Meier product-limit method was used to estimate 
mortality/survival probabilities, with differences between groups tested using the log-rank procedure. 
Cox proportional hazard regression was used to compute hazard ratios (HR) and 95% confidence 
intervals (CI) for long-term mortality. The initial multivariable models included variables that have been 
previously reported to be associated with cardiovascular-related mortality, regardless of their statistical 
significance in our dataset. These included race, age, sex, hypertension, CAD severity, heart failure, and 
prior stroke [9]. The post-hoc addition of other variables into the model was performed in a pairwise 
manner. The test statistic of Grambsch and Therneau was used to validate the proportional hazards 
assumption [17]. Statistical significance for categorical variables was tested using the Fisher’s Exact  
Test and the Deuchler-Wilcoxon method for continuous variables. PTrend for increasing or decreasing  
HRs across levels of continuous variables was computed using a likelihood ratio test. An iterative 
expectation-maximization (EM) algorithm was applied to impute missing values [18]. Similarly, the 
interaction between preoperative inotrope use and race was tested using a likelihood ratio test.  
The method of Holly and Whittemore was used for rounding [19]. Statistical significance was defined 
as p < 0.05. SAS Version 9.4 (Cary, NC, USA) was used for this analysis. 
3. Results and Discussion 
3.1. Results 
A total of 15,765 patients received CABG during the study period from 1992 to 2011. The median 
follow-up time in years was 7.8 with an interquartile range (IQR) of 8.3 (blacks: median = 6.4,  
IQR = 7.8; whites: 8.0, IQR = 8.3). Black and white patients differed with respect to BMI (median), dialysis 
(%) and peripheral arterial disease (PAD) (%) in both the preoperative inotrope and non-inotrope group 
(Table 1). No statistically significant differences were observed for preoperative medications between black 
and white patients on preoperative inotropes (Table 2). Similarly, blacks and whites on preoperative inotropes 
did not differ with respect to postoperative complications (Table 3).  
Among back patients, 56% received an intra/postoperative inotropic agent versus 49% for white 
patients (Fisher’s exact p < 0.0001, not shown in tables). However, few patients received both a 
preoperative and intra/postoperative inotropic agent (1.2%). 
Long-term mortality differed by race (black vs. white) among preoperative inotropic category  
(inotropes: adjusted HR = 1.6, 95% CI = 1.009–2.4; no inotropes: adjusted HR = 1.15, 95% CI = 1.08–1.2; 
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Pinteraction < 0.0001) (See Table 4). Kaplan-Meier survival plot is shown in Figure 1. The multivariable 
results did not substantively change with the pairwise inclusion of other variables listed in Tables 1 and 
2. Because inotropes are used to treat heart failure and may have resulted in over-adjustment,  
our multivariable models were repeated excluding the variable heart failure, with no significant effects 
on our results. No critical departures from model fit where noted for the Cox regression analyses 
performed in our study.  
Table 1. Patient characteristics (N = 15,765). 
Characteristic 
Inotropes 
p-Value * 
No Inotropes 
p-Value * Black  
n (%) 
White  
n (%) 
Black  
n (%) 
White  
n (%) 
Overall 46 (22) 165 (78) – 2673 (17) 12881 (83) – 
Age (Years) 
 Median (IQR) 
 
68 (20) 
 
66 (15) 
 
0.49 
 
62 (16) 
 
65 (15) 
 
<0.0001 
Female 20 (43) 53 (32) 0.16 1131 (42) 3624 (28) <0.0001 
BMI (kg/m2) £ 
 Median (IQR) 
 
29 (6.8) 
 
27 (5.7) 
 
0.019 
 
29 (7.5) 
 
28 (6.6) 
 
<0.0001 
Ejection fraction (%) £ 
 Median (IQR) 
 
39 (20) 
 
35 (25) 
 
0.21 
 
50 (20) 
 
52 (20) 
 
<0.0001 
Isolated CABG 34 (74) 130 (79) 0.55 2345 (88) 11265 (87) 0.72 
Surgery prior to Year 2001 16 (35) 80 (48) 0.13 1275 (48) 7503 (58) <0.0001 
CAD severity 
 1 Vessel 
 2 Vessel 
 3 Vessel 
 
1 (2) 
12 (26) 
33 (72) 
 
12 (7) 
51 (31) 
102 (62) 
 
0.36 
 
219 (8) 
702 (26) 
1752 (66) 
 
1215 (9) 
3507 (27) 
8159 (63) 
 
0.046 
Left main disease 9 (20) 43 (26) 0.44 528 (20) 2535 (20) 0.94 
Recent smoker 11 (24) 54 (33) 0.28 680 (25) 3023 (23) 0.030 
Hypertension 39 (85) 93 (56) 0.0005 2289 (86) 8985 (70) <0.0001 
Diabetes 28 (61) 54 (33) 0.0004 1256 (47) 4078 (32) <0.0001 
Dialysis 4 (9) 1 (1) 0.0085 166 (6) 104 (1) <0.0001 
Heart failure ‡ 26 (57) 87 (53) 0.74 699 (26) 2310 (18) <0.0001 
Peripheral arterial disease 12 (26) 17 (10) 0.013 385 (14) 1511 (12) 0.0002 
Prior MI 33 (72) 126 (76) 0.56 1141 (43) 4822 (37) <0.0001 
Prior stroke 5 (11) 13 (8) 0.55 302 (11) 975 (8) <0.0001 
Prior PCI 12 (26) 54 (33) 0.47 521 (19) 2463 (19) 0.67 
* Fisher’s Exact (categorical) and Deuchler-Wilcoxon (continuous) test for comparing variables for Black vs. 
White patients within ionotropic group. £ Estimates computed using the EM algorithm (n = 10 simulations,  
£ imputational efficiency ≥ 99%). ‡ Stable or asymptomatic compensated. BMI = body mass index;  
CABG = coronary artery bypass graft; CAD = coronary artery disease; IQR = interquartile range;  
MI = myocardial infarction; PCI = percutaneous coronary intervention; SD = standard deviation.  
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Table 2. Preoperative medications. 
Medications  
Inotropes 
p-Value * 
No Inotropes 
p-Value * Black  
n (%) 
White 
n (%) 
Black  
n (%) 
White  
n (%) 
Aspirin 32 (70) 104 (63) 0.49 1800 (67) 8891 (69) 0.090 
Lipid Lowering Agents 11 (24) 45 (27) 0.71 1186 (44) 5088 (40) <0.0001 
β-blockers 19 (41) 64 (39) 0.86 1631 (61) 6940 (54) <0.0001 
Anticoagulants 31 (67) 116 (70) 0.72 844 (32) 4026 (31) 0.75 
Antiplatelet Agents 21 (46) 92 (56) 0.25 1198 (45) 6542 (51) <0.0001 
Calcium Channel Blockers 8 (17) 21 (13) 0.47 880 (33) 3857 (30) 0.0025 
Diuretics 23 (50) 77 (47) 0.74 814 (30) 2824 (22) <0.0001 
ACE Inhibitors/ARBs 14 (36) 54 (33) 0.86 1095 (41) 3808 (30) <0.0001 
Digitalis 10 (22) 19 (12) 0.090 180 (7) 1003 (8) 0.065 
Nitrates 19 (41) 76 (46) 0.62 356 (13) 1983 (15) 0.0062 
* Fisher’s exact test comparing categorical variables for race within inotrope group. 
Table 3. Postoperative complications. 
Complications 
Inotropes 
p-Value * 
No Inotropes 
p-Value * Blacks 
n (%) 
Whites  
n (%) 
Blacks  
n (%) 
Whites  
n (%) 
MI 0 (0) 1 (1) 1.0 5 (<1) 59 (<1) 0.046 
Stroke 0 (0) 3 (2) 1.0 71 (3) 184 (1) <0.0001 
ARDS 3 (7) 15 (9) 0.77 19 (1) 119 (1) 0.31 
Pneumonia 1 (2) 16 (10) 0.13 68 (3) 257 (2) 0.75 
Gastrointestinal  2 (4) 18 (11) 0.26 103 (4) 307 (2) <0.0001 
* Fisher’s exact test comparing categorical variables for race within inotrope group. ARDS = acute 
respiratory distress syndrome; MI = myocardial infarction.  
Table 4. Univariable and multivariable hazard ratios for mortality. 
Characteristic † 
Inotropes No Inotropes 
Univariable 
HR (95% CI) 
Multivariable 
HR (95% CI) 
Univariable 
HR (95% CI) 
Multivariable 
HR (95% CI) 
Black * 1.5 (1.004–2.2) 1.6 (1.009–2.4) 1.15 (1.08–1.2) 1.15 (1.08–1.2) 
Age in years (continuous) 1.04 (1.02–1.06) 1.04 (1.02–1.1) 1.057 (1.055–1.060) 1.054 (1.051–1.057 
Female 1.2 (0.82–1.7) 0.99 (0.68–1.4) 1.13 (1.07–1.2) 0.93 (0.88–0.98) 
Hypertension 1.1 (0.77–1.6) 0.81 (0.55–1.2) 1.26 (1.2–1.3) 1.1 1.07–1.2) 
CAD severity 
 1 Vessel 
 2 Vessel 
 3 Vessel 
 
1.0 Referent 
1.1 (0.47–2.7) 
1.6 (0.72–3.4) 
Ptrend  = 0.048 § 
 
1.0 Referent 
0.92 (0.38–2.2) 
1.3 (0.57–3.1) 
Ptrend = 0.10 § 
 
1.0 Referent 
1.2 (1.08–1.3) 
1.4 (1.3–1.6) 
Ptrend  < 0.0001 § 
 
1.0 Referent 
1.2 (1.1–1.4) 
1.4 (1.3–1.5) 
Ptrend  < 0.0001 § 
Heart failure ‡ 1.3 (0.89–1.8) 1.1 (0.75–1.6) 2.2 (2.1–2.3) 1.8 (1.7–2.0) 
Prior stroke 1.2 (0.65–2.3) 1.2 (0.62–2.2) 1.9 (1.8–2.1) 1.6 (1.5–1.8) 
* Multivariable Pinteraction < 0.0001 (Likelihood ratio test, Inotropes x Race). § Likelihood ratio trend test.  
‡ Stable or asymptomatic compensated. CAD = coronary artery disease; CI = confidence interval; HR = hazard 
ratio. † Referent groups were white, male, no hypertension, no heart failure and no prior stoke, respectively.  
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Figure 1. Inotrope use by race.  
3.2. Discussion 
In our study a statistically significant interaction was observed between preoperative inotrope use and 
race with respect to long-term mortality. To our knowledge this is the first study to examine  
long-term mortality among black CABG patients receiving preoperative inotropes. The use of 
preoperative inotropes was associated with increased risk of long-term mortality in blacks compared 
with whites. Possible explanations for this finding may include differences in heart failure etiology, drug 
metabolism and physiologic response to inotropes. 
Racial differences in short-term mortality in patients with acute decompensated heart failure who 
received inotropic therapy was examined in the OPTIME-CHF (Outcomes of a Prospective Trial of 
Milrinone for Exacerbations of Chronic Heart Failure) study [4]. This prospective randomized trial 
reported statistically significant lower 60-day mortality (unadjusted analysis) among black patients who 
received milirinone, compared with whites. However, no difference in mortality was detected after the 
adjustment for baseline differences. Even though the OPTIME-CHF trial excluded patients who received 
inotropic therapy for cardiogenic shock and those with preserved systolic function, the adjusted results 
correspond closely to our findings over the same 60-day time period. The majority (74%) of blacks 
enrolled in the OPTIME-CHF trial had non-ischemic heart failure. In contrast, patients in our study were 
assumed to have cardiac ischemia secondary to underlying coronary artery disease requiring  
surgical bypass.  
The OPTIME-CHF study also compared the use of inotropes in ischemic versus non-ischemic heart 
failure patients [20]. Those enrolled in the study with non-ischemic heart failure tolerated or even 
benefited from the use of inotropes in comparison with ischemic heart failure patients who experienced 
increased mortality and hospitalization rates. The results of the study suggest that a differential response 
to inotropes by race may be attributable to differing etiologies of heart failure.  
While patients in our study were primarily treated for ischemic heart disease, an increased rate of 
diabetes and hypertension was observed among black patients, which is frequently associated with 
Int. J. Environ. Res. Public Health 2015, 12 7485 
 
 
diabetic or hypertensive cardiomyopathy. Altered inotropic responses have been reported in diabetic 
cardiomyopathy and hypertensive-diabetic cardiomyopathy within the laboratory setting. Specifically, 
inotropes administered to diabetic and hypertensive rodents have higher sensitivity and effect on the 
myocardium which presumably leads to increased mortality [21]. Conceivably, similar effects might 
underlie the differential mortality outcome that is seen in black patients on inotropic agents. Another 
contributing factor, as noted in prior studies, may be that black patients receive life-saving 
cardioprotective therapies less often than whites [22]. While inotropic agents may improve 
mitochondrial function in noninfarcted myocardial tissue, free calcium in the cytosol can lead to 
activation of proteolytic enzymes, proapoptotic signal cascades, mitochondrial damage and eventually, 
necrosis and disrupted membranes [23]. 
Our findings are important to contrast with the African-American Heart Failure Trial (A-HeFT) [24] of 
combination isosorbide dinitrate and hydralazine in black patients. This trial showed that nitric oxide 
medications are more effective in black patients than whites. Isosorbide dinitrate functions by being 
converted to nitric oxide (NO), an active intermediate compound which activates the enzyme guanylate 
cyclase [25]. This stimulates the synthesis of cyclic guanosine 3’, 5’-monophosphate (cGMP) that in 
turn activates a series of protein kinase-dependent phosphorylations in the vascular smooth muscle cells 
and results in the dephosphorylation of the myosin light chain of the smooth muscle fiber. Subsequently, 
the release of calcium ions by the myosin light chain results in the relaxation of the smooth muscle cells 
and vasodilation. It is generally known that NO induces protein kinase G (PKG) which has a dual effect: 
(1) inhibition of inositol trisphosphate receptor (IP3) receptor resulting in calcium release from 
sarcoplasmic reticulum (SR) into cytoplasm, and (2) increased phospholamban phosphorylation, 
SERCA2a activity and calcium uptake into the SR [26–28]. Both effects will reduce the calcium release 
from SR into the cytoplasm and sequester more of the calcium inside the SR. Additionally, isosorbide 
dinitrate has been noted to have a weak positive inotropic effect on the myocardium [29]. Blacks with 
heart failure have been observed to exhibit greater NO reduction while whites have modestly reduced 
NO [30]. It can, therefore, be postulated that isosorbide dinitrate has a positive inotropic effect that is 
greater among black patients, although the vasodilatory effect of NO is likely to be the predominant 
factor. However, as reported in A-HeFT, blacks with heart failure had better outcomes (e.g., decreased 
mortality, improved quality of life at 6 months) when randomized to a combination of isosorbide 
dinitrate and hydralazine, which inhibits destruction of NO. While it is presumed that this effect is more 
pronounced in black patients, white patients were not enrolled in the above study as a referent group. 
Moreover, our database did not allow us to ascertain the prevalence of phosphodiesterase inhibitors as 
inotropic therapy in our patient cohort. This is a potentially important variable given that these agents 
are known to exhibit a NO-potentiating effect.  
We cannot rule out that the differential long-term mortality observed in our study may be explained 
by factors unrelated to the preoperative use of inotropic agents. For example, residents of rural areas 
have limited access to medical care compared with urban regions and this effect may have been 
potentiated among black patients owing to historic racial barriers in the South [31,32]. Furthermore, 
blacks traditionally prioritize health to a lesser degree than whites, postpone seeing a doctor, often do 
not have a regular physician, and generally are less trusting of health care providers [33–35].  
Other contributing factors may include suboptimal follow-up care, inappropriate specialist referral,  
non-adherence to treatment regimens, community segregation, differences in socioeconomic position 
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and educational achievement, and other social determinants of health [36]. The use of inotropic agents 
in this population also might simply represent a surrogate marker of severity that is further compounded 
by the above mentioned factors. However, in previous studies of racial differences in long-term mortality 
following CABG surgery, blacks with chronic lung disease or renal failure requiring dialysis were 
observed to have equal or more favorable outcomes than whites [7,8].  
Our study is strengthened by its large racially dichotomous population and systematic data collection. 
Nonetheless, various limitations should be noted when interpreting our results. Although we adjusted 
for patient demographics and several comorbidities associated with long-term mortality following 
CABG, residual confounding may still exist due to the non-randomized nature of this study and limited 
sample size within the inotrope group. Stable or asymptomatic compensated heart failure patients or 
patients whose symptoms improved after medical therapy were not categorized as being in heart failure 
by the STS definition and this may have further resulted in incomplete adjustment when added pairwise 
to our multivariable Cox regression model. Type, dose, duration and reason for inotrope use were not 
recorded in our STS database and this information frequently was incomplete or not available in 
retrospective scans of medical charts. Accordingly, we were unable to determine the differential clinical 
impact, for example, of being on dopamine for 3 h preoperatively versus 2 days of high dose epinephrine. 
The possibility also exists that some patients may have received low-dose inotropic agents for indications 
other than heart failure or cardiogenic shock after acute MI (e.g., decreased renal profusion). However, 
any bias resulting from including these cases in our analyses likely would have been toward the null. 
The absence of individual and area-level socioeconomic measures such as residential history was 
another potential limitation of our study. We were unable to sufficiently estimate socioeconomic position 
using zip codes because a large percentage of patients in our region have postal office boxes. However, 
eastern North Carolina is largely homogenous with respect to socioeconomic status and it is unlikely 
that the inclusion of this information in our models would have substantively altered any study findings. 
Race was self-reported and there could have been potential misclassification of this variable. 
Additionally, genetic data were not collected and, therefore could not be accessed as a potential 
cofounder in our analyses. Chance or an unexplained paradox specific to our patient population also may 
underlie our findings. 
The status of several variables in our analysis may have changed over time. We did not adjust for 
these variables in a time-dependent manner due to their potential to be in the causal pathway. Similarly, 
intraoperative and postoperative variables were not included in our multivariable models. 
Cause of death is not recorded in the National Death Index and POAF status may have been unrelated 
to their mortality. Although we adjusted for known clinically relevant variables, we acknowledge that 
other unmeasured factors could have influenced our results due to the retrospective nature of this study.  
The results of this study are from a rural region with a unique population and may not generalize to 
other regions of the country. However, because our data were collected from a single unified health 
system, this might have partially controlled for other healthcare-related factors. 
4. Conclusions 
Our study identified an independent preoperative risk factor for long-term mortality among blacks 
receiving CABG. This outcome provides information that may be useful for surgeons, primary care 
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providers, and their patients. Further research, especially in the context of psychosocial and biological 
factors (as well as their interaction), is needed to validate our findings and to determine the potential 
explanation for the racial disparity observed in our study. 
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